NCT05286229 - A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG

Etentamig

Intravenous (IV) Infusion

Trial Locations (6)

National Cancer Center Hospital East /ID# 240943, Kashiwa-shi

Hokkaido University Hospital /ID# 242672, Sapporo

Kanazawa University Hospital /ID# 240948, Kanazawa

Duplicate_Okayama Medical Center /ID# 240949, Okayama

The University of Osaka Hospital /ID# 242032, Suita-shi

Yamagata University Hospital /ID# 240945, Yamagata